Related Experiment Video
Updated: Jun 13, 2026
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact
1Department of Hematology and Cell Therapy, San Bortolo Hospital, Vicenza, Italy.
Abstract:
Tumor vasculature and tumor-associated neo-angiogenesis have recently become major targets of antineoplastic therapy. Beside the agents which have already obtained US Food and Drug Administration (FDA) approval for clinical use (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib), many others are being tested in clinical trials. Angiogenesis inhibitors, in particular inhibitors of the vascular endothelial growth factor (VEGF) pathway, have shown significant vascular complications, including both thromboembolic and bleeding events. The definition of the clinical impact of bleeding complications (increase in the rate of hemorrhages in comparison with the control group) and the knowledge of the pathogenesis of this toxicity are very important in order to evaluate the results of many studies using antiangiogenic agents in the treatment of cancer patients.
Insights
Antiangiogenic therapies targeting tumor vasculature can cause bleeding complications. Understanding these risks is crucial for evaluating cancer treatment outcomes.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Tumor vasculature and neo-angiogenesis are key targets in cancer therapy.
- Approved and investigational anti-cancer agents target these pathways.
- Vascular endothelial growth factor (VEGF) pathway inhibitors are prominent examples.
Purpose of the Study:
- To highlight the significance of bleeding complications associated with antiangiogenic agents.
- To emphasize the need for understanding the pathogenesis of bleeding toxicity.
- To inform the evaluation of clinical studies involving antiangiogenic therapy in cancer patients.
Main Methods:
- Review of clinical trials and approved anti-cancer agents targeting angiogenesis.
- Analysis of reported vascular complications, specifically bleeding events.
- Discussion of the clinical impact and pathogenesis of antiangiogenic-induced bleeding.
Main Results:
- Antiangiogenesis therapies, particularly VEGF pathway inhibitors, are associated with significant bleeding events.
- These complications represent a notable increase in hemorrhage rates compared to control groups.
- Thromboembolic events are also recognized complications.
Conclusions:
- Bleeding complications are a critical clinical consideration for antiangiogenic therapies.
- Further research into the pathogenesis of this toxicity is essential.
- Accurate assessment of bleeding risks is vital for interpreting clinical trial data and patient outcomes.
Related Concept Videos
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...